BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Marathon Oil Corporation (NYSE – MRO)
Under the terms of the agreement, Marathon Oil will be acquired by ConocoPhillips (NYSE – COP). ConocoPhillips will acquire Marathon Oil in an all-stock transaction with an enterprise value of $22.5 billion, inclusive of $5.4 billion of net debt. Marathon Oil shareholders will receive 0.2550 shares of ConocoPhillips common stock for each share of Marathon Oil common stock, based on the closing share price of Marathon Oil on May 28, 2024. The investigation concerns whether the Marathon Oil Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether ConocoPhillips is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/marathon-oil-corporation-nyse-mro/.
Atrion Corporation (Nasdaq – ATRI)
Under the terms of the agreement, Atrion will be acquired by Nordson Corporation for $460.00 per share in cash or a total equity value of $815 million. The investigation concerns whether the Atrion Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Nordson Corporation is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/atrion-corporation-nasdaq-atri/.
Surmodics, Inc. (Nasdaq – SRDX)
Under the terms of the agreement, Surmodics will be acquired by GTCR for $43.00 per share in cash, for a total equity valuation of approximately $627 million. The investigation concerns whether the Surmodics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether GTCR is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/surmodics-inc-nasdaq-srdx/.
Akili, Inc. (Nasdaq – AKLI)
Under the terms of the agreement, Akili will be acquired by Virtual Therapeutics for $0.4340 per share in cash. The investigation concerns whether the Akili Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Virtual Therapeutics is paying fair value to shareholders of the Company. For example, the deal consideration is below the 52-week high of $1.67 for the Company’s shares.
Additional information can be found at https://www.brodskysmith.com/cases/akili-inc-nasdaq-akli/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
- Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - June 1, 2025
- TRAXXAS ALERT: Bragar Eagel & Squire, P.C. is Investigating Traxxas, L.P. on Behalf of Traxxas Customers and Encourages Consumers to Contact the Firm - June 1, 2025
- ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Compass Diversified Holdings Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm- CODI - June 1, 2025
